VIRBAC EXERCISES ITS OPTION FOR A COMMERCIAL LICENCE AGREEMENT TO USE VIVALIS' EBx(R) PLATFORM

VIRBAC EXERCISES ITS OPTION FOR A COMMERCIAL LICENCE AGREEMENT TO USE VIVALIS' EBx® PLATFORM FOR THE PRODUCTION OF SEVERAL VACCINES.

Nantes (France) - April 1st, 2008 - VIVALIS (Euronext : VLS) announces today that VIRBAC has exercised its option for a commercial license to use VIVALIS' EBx® platform for the production of companion animal vaccines.

" We are pleased to reach this new milestone in the collaboration with VIRBAC, one of the first independent companies exclusively dedicated to animal health. This agreement with VIRBAC confirms the growing interest of pharmaceutical industry for EBx® cellular platform for the production of biological products, either vaccines or therapeutic proteins " said Franck Grimaud, Président du Directoire de VIVALIS.

The licence is world-wide and non-exclusive. The financial terms of the agreement, which remain confidential, include milestone payments and royalties.

*******************

Next calendar:

April 16th, 2008 - Quarterly report: 1st quarter 2008

*******************

About VIVALIS ( www.vivalis.com )

Vivalis (Euronext: VLS) is a public biopharmaceutical company that provides innovative cell based solutions for the industrial manufacture of viral vaccines and therapeutic proteins and develops vaccines and drugs to prevent and treat viral diseases.. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas:

- Vaccine development and manufacturing. VIVALIS grants research & commercial licences to its proprietary ebx® embryonic stem cell lines to pharmaceutical and biotechnology companies active in the viral vaccine business.

- Recombinant therapeutic protein and monoclonal antibody expression systems development. VIVALIS partners with pharmaceutical and biotechnology companies in this area, to which it licences its proprietary ebx® embryonic stem cell lines to manufacture recombinant therapeutic proteins.

- The build-up of a proprietary portfolio of vaccines and anti-viral molecules.

Based in Nantes (France), Vivalis was created in 1999 by Group GRIMAUD (1350 employees), the n degrees2 group worldwide in avian genetic breeding. Vivalis has established several partnerships with companies that are worldwide leaders in their respective fields, including Sanofi Pasteur, GlaxoSmithKline, Kaketsuken, Novartis Vaccines, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster.

Euronext Paris - Compartment C - FR0004056851

Reuters: VLS.PA - Bloomberg: VLS FP

Investors Relation :

VIVALIS

Franck Grimaud, C.E.O

Email : investors@vivalis.com

NewCap

Financial Communication Agency Steve Grobet / Emmanuel Huynh

Tel. : +33 (0) 1 44 71 94 91

Email : vivalis@newcap.fr

This information is provided by HUGIN